1. 1ISG-016 Envisioning sustainability in personalised medicine: Fondo AIFA 5% and the Italian example. (24th March 2020) Authors: Bocchio, F; Tizzoni, M; Calvi, M; Di Benedetto, A Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DI-079 Brentuximab Vedotin: from Named Patient Program (NPP) to Italian Law 648/96. (24th February 2014) Authors: Rebagliati, G; Bonfichi, M; Zecca, M; Bocchio, F; Gotti, M; Calafiore, L; Cusato, M; Tizzoni, M; Calvi, M Journal: European journal of hospital pharmacy Issue: Volume 21(2014)Supplement 1 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. (March 2021) Authors: Paolucci, Stefania; Cassaniti, Irene; Novazzi, Federica; Fiorina, Loretta; Piralla, Antonio; Comolli, Giuditta; Bruno, Raffaele; Maserati, Renato; Gulminetti, Roberto; Novati, Stefano; Mojoli, Francesco; Baldanti, Fausto; Bruno, R; Mondelli, M; Brunetti, E; Di Matteo, A; Seminari, E; Maiocchi, L;... Journal: International journal of infectious diseases Issue: Volume 104(2021) Page Start: 315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CP-133 Name patient program with siltuximab in multicentric castleman's disease: a case report. (24th March 2015) Authors: Bocchio, F; Bonfichi, M; Calvi, M; Tizzoni, M; Rebagliati, G Journal: European journal of hospital pharmacy Issue: Volume 22(2015)Supplement 1 Page Start: A53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗